

RESEARCH ARTICLE


# Haemolysis in G6PD Heterozygous Females Treated with Primaquine for *Plasmodium vivax* Malaria: A Nested Cohort in a Trial of Radical Curative Regimens

Cindy S. Chu<sup>1,2\*</sup>, Germana Bancone<sup>1,2</sup>, Kerryn A. Moore<sup>3,4</sup>, Htun Htun Win<sup>1</sup>, Niramon Thitipanawan<sup>1</sup>, Christina Po<sup>1</sup>, Nongnud Chowwiwat<sup>1</sup>, Rattanaporn Raksapraidee<sup>1</sup>, Pornpimon Wilairisak<sup>1</sup>, Aung Pyae Phyo<sup>1</sup>, Lily Keereecharoen<sup>1</sup>, Stéphane Proux<sup>1</sup>, Prakaykaew Charunwatthana<sup>5,6</sup>, François Nosten<sup>1,2</sup>, Nicholas J. White<sup>2,5</sup>

# Overview of study procedures

- Included **G6PD phenotypically normal** patients 6 months or older with **uncomplicated *P. vivax*** infection
- Treatment arms
  - Chloroquine (3d) + Primaquine **1 mg/kg/day (7d)**
  - Chloroquine (3d) + Primaquine **0.5 mg/kg/day (14d)**
  - DHAP (3d) + Primaquine **1mg/kg/day (7d)**
  - DHAP (3d) + Primaquine **0.5 mg/kg/day (14d)**
- Supervised treatment and field haematocrit daily until treatment completed


Mean fractional hematocrit change (%)




- ▲ Het PMQ-1
- Het PMQ-0.5
- ▲ WT PMQ-1
- WT PMQ-0.5

Fractional haematocrit reduction during primaquine administration in wild type and G6PD heterozygous females

Fractional hematocrit change (%)



Fractional haematocrit change when including a test for interaction between G6PD genotype and PMQ dose but NOT adjusting for parasitaemia



This research was funded by the Wellcome Trust